


Rivaroxaban Clinical Trial Overview

The extensive evaluation of rivaroxaban makes it the most studied novel oral anticoagulant (OAC) in the world. No other novel OAC is approved for five indications in seven distinct areas of use, protecting patients across more venous and arterial thromboembolic (VAT) conditions than any other novel OAC.*

Venous & Arterial Thromboembolism (VAT)



Completed Trials in Venous Thromboembolism (VTE)

RECORD 1	PHASE III	Prevention of DVT and PE following elective total hip replacement*	4,541 patients First approved in 2008
RECORD 2	PHASE III	Prevention of DVT and PE following elective total hip replacement*	2,509 patients First approved in 2008
RECORD 3	PHASE III	Prevention of DVT and PE following elective total knee replacement*	2,531 patients First approved in 2008
RECORD 4	PHASE III	Prevention of DVT and PE following elective total knee replacement*	3,148 patients First approved in 2008
MAGELLAN	PHASE III	DVT and PE Prevention in acutely ill, hospitalised patients**	8,101 patients Primary efficacy endpoints met but no consistent positive benefit-risk balance
EINSTEIN DVT	PHASE III	Treatment of DVT and prevention of recurrent DVT or PE*	3,449 patients First approved in 2011
EINSTEIN PE	PHASE III	Treatment of PE and the prevention of recurrent DVT and PE*	4,833 patients First approved in 2012
EINSTEIN EXT	PHASE III	Long-term prevention of DVT and PE*	1,197 patients First approved in 2011
XAMOS	OBSERVATIONAL	Prevention of DVT and PE following elective hip and knee surgery	17,413 patients Results reported April 2012: Consistent with RECORD findings

Completed Trials in Arterial Thrombosis and Thromboembolism

ROCKET AF	PHASE III	Prevention of stroke and systemic embolism in adult patients with non-valvular AF*	14,264 patients First approved in 2011
J-ROCKET AF	PHASE III	Prevention of stroke and systemic embolism in adult patients with non-valvular AF*	1,280 patients Approved in Japan in 2012
ATLAS ACS TIMI 51	PHASE III	Secondary prevention after an ACS*	15,526 patients First approved in 2013
X-VERT	PHASE IIIb	Stroke prevention in patients with non-valvular AF undergoing cardioversion	1,504 patients Initiated October 2012 Completed January 2014
X-PLORER	PHASE II	Thrombosis prevention in patients with CAD undergoing elective PCI**	108 patients Initiated October 2011 Completed March 2013

Ongoing Venous Trials***

EINSTEIN CHOICE	PHASE III	Long-term, secondary prevention of DVT and PE	2,850 patients (planned) Announced February 2014
EINSTEIN JUNIOR	PHASE III	Treatment and prevention of DVT and PE in paediatric populations	150 patients (planned) Announced March 2014
MARINER	PHASE III	Prevention of DVT and PE in high-risk medically ill patients following hospital discharge	8,000 patients (planned) Initiated April 2014
XALIA	OBSERVATIONAL	Patients with acute DVT	4,800 patients (planned) Initiated June 2012

Ongoing Arterial Trials***

COMPASS	PHASE III	Prevention of major adverse cardiac events (MACE) in patients with CAD or PAD	20,000 patients (planned) Initiated February 2013
COMMANDER HF	PHASE III	Reducing risk of death, MI or stroke in patients with chronic heart failure and significant CAD	5,000 patients (planned) Initiated September 2013
PIONEER AF-PCI	PHASE IIIb	Evaluating the safety of rivaroxaban and VKAs in patients with non-valvular AF undergoing PCI with stent placement	2,100 patients (planned) Initiated May 2013
VENTURE AF	PHASE IIIb	Stroke prevention in patients with non-valvular AF undergoing catheter ablation	200 patients (planned) Initiated February 2013
XANTUS XANAP	OBSERVATIONAL	Real world studies in patients with non-valvular AF	XANTUS - 6,000 patients in Europe (planned) Initiated June 2012 XANAP - 5,500 patients in Asia (planned) Initiated January 2013
NAVIGATE ESUS	PHASE III	Secondary stroke prevention in patients with ESUS	7,000 patients (planned) Announced August 2014
VOYAGER PAD	PHASE III	Prevention of thrombotic vascular complications in patients with PAD undergoing peripheral artery interventions	4,000 patients (planned) Announced August 2014
GEMINI ACS 1	PHASE II	Secondary prevention in patients after an ACS	2,000 - 3,000 patients (planned) Announced August 2014

*Whilst licenses may differ from country to country, across all indications rivaroxaban is approved in more than 125 countries; **Rivaroxaban is not currently approved in this indication; ***Ongoing clinical trials include areas of unmet medical need where rivaroxaban is not currently approved